Home / Business and Economy / Swedish Pharma Giant Targets Rare Diseases
Swedish Pharma Giant Targets Rare Diseases
3 Aug
Summary
- Focuses on hemophilia and autoimmune disease treatments.
- Offers about 40 pharmaceuticals across segments.
- Operates subsidiaries in multiple European nations.
Swedish Orphan Biovitrum AB (publ) is a prominent pharmaceutical entity based in Sweden. The company is dedicated to the development, manufacturing, and sale of crucial medications.
Its therapeutic areas include hemophilia, autoimmune diseases, metabolic diseases, and supportive care for cancer patients.
The company's product portfolio is strategically divided into three main business segments. These segments encompass core products in inflammation and genetics/metabolic therapies, partner products featuring approximately 40 pharmaceuticals in hematology, oncology, and emergency medicine, and the ReFacto Manufacturing segment.
Swedish Orphan Biovitrum AB has established a significant international footprint, with subsidiaries located in Sweden, Denmark, Finland, Norway, the United Kingdom, and France, among other nations.
